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ABSTRACT
Despite the well-established tumor suppressive role of TGFβ proteins, depletion 
of key TGFβ signaling components in the mouse ovary does not induce a growth 
advantage. To define the role of TGFβ signaling in ovarian tumorigenesis, we created a 
mouse model expressing a constitutively active TGFβ receptor 1 (TGFBR1) in ovarian 
somatic cells using conditional gain-of-function approach. Remarkably, these mice 
developed ovarian sex cord-stromal tumors with complete penetrance, leading to 
reproductive failure and mortality. The tumors expressed multiple granulosa cell 
markers and caused elevated serum inhibin and estradiol levels, reminiscent of 
granulosa cell tumors. Consistent with the tumorigenic effect, overactivation of TGFBR1 
altered tumor microenvironment by promoting angiogenesis and enhanced ovarian 
cell proliferation, accompanied by impaired cell differentiation and dysregulated 
expression of critical genes in ovarian function. By further exploiting complementary 
genetic models, we substantiated our finding that constitutively active TGFBR1 is a 
potent oncogenic switch in mouse granulosa cells. In summary, overactivation of 
TGFBR1 drives gonadal tumor development. The TGFBR1 constitutively active mouse 
model phenocopies a number of morphological, hormonal, and molecular features of 
human granulosa cell tumors and are potentially valuable for preclinical testing of 
targeted therapies to treat granulosa cell tumors, a class of poorly defined ovarian 
malignancies.
INTRODUCTION
Sex cord-stromal tumors are derived from the 
granulosa, theca, and/or stromal fibroblast components of 
the ovary and represent ~8% of all categories of ovarian 
tumors [1]. Granulosa cell tumors which arise from ovarian 
granulosa cells [2] are most common sex cord-stromal 
tumors and account for ~ 5% of ovarian malignancies 
[1]. The molecular etiology of sex cord-stromal tumors 
is poorly defined, partially because of its rarity and the 
fact that research efforts in ovarian cancer research field 
have been predominantly focused on tumors of epithelial 
cell origin, the major type of ovarian tumors [1]. Although 
the prognosis of granulosa cell tumors is often better than 
that of epithelial tumors, a serious complication is the risk 
of prolonged recurrence (i.e., relapse), a significant cause 
of death in patients [3]. Treatment strategy for granulosa 
cell tumors is generally based on that for epithelial tumors 
which have distinct disease etiology, arguing for the need 
of developing tailored treatment options for this type of 
tumors. 
Genetically modified mouse models are powerful 
tools in cancer research. To date, there are several mouse 
models for sex cord-stromal tumors [4-12], such as mice 
with targeted deletion of α inhibin (Inha) [4], Smad1/5 [5], 
bone morphogenetic protein (BMP) type 1 receptors [6], 
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and forkhead box O1/3 (Foxo1/3) and phosphatase and 
tensin homolog (Pten) [12] and constitutive activation of 
wingless-type MMTV integration site (WNT)/β-catenin 
[7, 8]. The findings of Inha as a tumor suppressor gene 
specific for the gonad and adrenal and the inhibitory 
function of BMP receptors and SMADs in ovarian tumor 
formation reveal the importance of the transforming 
growth factor β (TGFβ) superfamily in gonadal 
carcinogenesis [4-6]. 
TGFβ superfamily members play critical roles 
in the development of reproductive system and cancer 
[13, 14]. TGFβ ligands (i.e., TGFβs 1-3) signal through 
a heteromeric complex consisting of type 2 (TGFBR2) 
and type 1 (TGFBR1) receptors and intracellular SMAD 
proteins, which comprise receptor regulated SMADs 
(SMAD2/3 and SMAD1/5/8) and a common SMAD 
(i.e., SMAD4). Activation of SMAD2/3 and SMAD1/5/8 
is associated with the transduction of TGFβ and BMP 
signaling, respectively [15]. TGFβ signaling generally 
acts as tumor suppressor via inhibiting cell proliferation 
during the early stage of tumor development. However, 
deletion of a number of key TGFβ signaling components 
(e.g., TGFβ1, TGFBR1, SMAD2/3, and SMAD4) alone 
in the ovary does not induce tumor formation [16-19], 
challenging TGFβ signaling as essential tumor suppressor 
in the ovary. In contrast to the involvement of BMP 
signaling (BMP type 1 receptors and BMP-responsive 
SMAD1/5/8) in ovarian tumor development [5, 6], the role 
of TGFβ signaling in the ovary remains elusive.
This study is therefore to identify the role of 
TGFβ signaling activation in the pathogenesis of ovarian 
tumors using conditional gain-of-function approach. 
We performed morphological, hormonal, and molecular 
analyses to determine the relevance of TGFBR1 
constitutively active mice as a model for ovarian granulosa 
cell tumors.
RESULTS
Generation of mice harboring a constitutively 
active TGFBR1 in the ovary
A constitutively active TGFBR1 (TGFBR1CA), 
where three missense mutations (i.e., T204D and L193A/
P194A) constitutively activate the TGFBR1 kinase [20] 
and prevent the binding of the TGFBR1 inhibitor FK506 
binding protein 1A (FKBP12) [21], was constructed as 
described [22]. The TGFBR1CA transgene was knocked 
into the hypoxanthine-guanine phosphoribosyltransferase 
(Hprt) locus, with a STOP sequence flanked by two Lox 
sites [22]. This allele has been successfully expressed 
in several compartments, including pancreas, liver, 
T lymphocytes, embryos, and uterus [23-26]. Upon 
Cre-mediated recombination, the STOP codon was 
removed, leading to the expression of constitutively 
active TGFBR1 under the control of the ubiquitous 
CAG (human cytomegalovirus enhancer and chicken 
beta-actin) promoter (Figure 1A). The TGFBR1CA Lox/Lox 
mice were crossed with mice harboring anti-Mullerian 
hormone receptor type 2 (Amhr2)-Cre (Figure S1A and 
B; TGFBR1-CAAcre). Expression of Amhr2-Cre in mouse 
ovarian granulosa cells was verified by X-gal staining of 
ovaries from Gt(ROSA)26Sor; Amhr2-Cre reporter mice 
[27] (Figure S1D). 
Validation of mice with enhanced TGFβ signaling 
in the ovary
As evidence of recombination of TGFBR1CA 
conditional allele in the Amhr2-Cre expressing tissues, 
PCR amplified a recombined band with the expected 
size in the ovaries of TGFBR1-CAAcre mice, but not 
those of controls (Figure S2A). Consistently, expression 
of TGFBR1CA mRNA transcripts was detected in the 
TGFBR1-CAAcre ovary versus controls by both quantitative 
and conventional PCR analyses (Figure S2B and C). 
Furthermore, the presence of TGFBR1CA fusion protein 
was confirmed in TGFBR1-CAAcre ovaries by western blot 
using an anti-hemagglutinin (HA) antibody (Figure S2D). 
To further validate this model, we demonstrated increased 
levels of phosphorylated SMAD2, an indicator of TGFβ 
signaling activity, in ovarian tissues of TGFBR1-CAAcre 
mice (Figure S2E). Coinciding with TGFβ signaling 
activation, expression of TGFβ target genes including 
TGFβ-induced (Tgfbi), serine/cysteine peptidase inhibitor 
clade E member 1 (Serpine1), connective tissue growth 
factor (Ctgf), and Smad7 was increased in the ovaries 
of TGFBR1-CAAcre mice (Figure S2F). Therefore, we 
successfully created a mouse model that harbors a 
constitutively active TGFBR1 in the ovary. 
Constitutive activation of TGFBR1 in the ovary 
promotes tumorigenesis
To determine the phenotypic consequence of 
constitutive activation of TGFBR1, we examined 
ovaries of control and TGFBR1-CAAcre mice at various 
developmental stages by macroscopic, histological, and 
immunohistochemical analyses using antibodies against 
alpha smooth muscle actin (ACTA2; green) and Y box 
protein 2 (MSY2; red) [28] to mark normal theca layers 
and oocytes, respectively. Strikingly, gross ovarian tumors 
were prominent in TGFBR1-CAAcre mice examined at 2 
months of age (Figure 1B). The tumors progressed rapidly 
and the phenotype was exacerbated with age (Figure 1B), 
leading to the death of TGFBR1-CAAcre mice. Tumor 
formation in the TGFBR1-CAAcre ovary was accompanied 
by a disruption of follicular development, with loss 
of follicle boundary and presence of multiple oocytes 
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Figure 1: Constitutive activation of TGFBR1 in the mouse ovary using Amhr2-Cre leads to ovarian tumor development. 
A. Schematic illustration of the latent constitutively active TGFBR1 allele. Upon Amhr2-Cre mediated recombination, the stop sequence 
was removed, and the TGFBR1CA was expressed in the ovary. Mice harboring the constitutively active TGFBR1 were termed TGFBR1-
CAAcre (TGFBR1CA Lox/+; Amhr2-Cre), and TGFBR1CA Lox/+ mice were used as controls. Pt, Hprt promoter; HA, hemagglutinin tag; CAG, 
composite constitutive CAG (human cytomegalovirus enhancer and chicken beta-actin). B. Representative macroscopic images of ovarian 
tumors in TGFBR1-CAAcre mice at 2 (n = 16), 4 (n = 7), and 5 (n = 6) months of age. Red arrows indicate ovarian tumors. C.-J. Histological 
and immunofluorescence analyses of ovaries from control (C, F, and I) and TGFBR1-CAAcre mice (D, E, G, H, and J). Panel (H) represents 
a higher power image for panel (G). Note the presence of follicle-like structures containing multiple oocytes (D and J; red arrows) and 
the altered follicular structure in the TGFBR1-CAAcre ovaries versus controls (C, F, and I), as was demonstrated by H&E staining and 
double immunofluorescence of ACTA2 (green) and MSY2 (red). Oo, oocyte; GC, granulosa cells. Yellow arrows indicate multifocal 
hemorrhage within follicle-like structures, while blue arrows indicate mitotic figures. DAPI was used to counterstain the nucleus. Scale bar 
is representatively depicted in (C) and equals 10 µm (H), 40 µm (C, D, I, and J), and 400 µm (E-G). K. Fertility defects in TGFBR1-CAAcre 
mice. The TGFBR1-CAAcre mice were sterile during a 3 month fertility test. Data represent accumulative pup numbers per month. n = 6.
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containing follicles (Figure 1D and 1J; red arrows), 
compared with age-matched controls (Figure 1C and 1I). 
The neoplastic cells were arranged in lobules with multiple 
layers of cuboidal cells forming follicle-like structures 
(Figure 1G) that contained mitotic figures (Figure 1H; blue 
arrows). Neoplastic cells were cuboidal, with round to oval 
nuclei (Figure 1H). Multifocally, there was hemorrhage 
within these follicle-like structures (Figure 1E and 1G; 
yellow arrows). These results suggest that the neoplasms 
belong to sex cord-stromal tumors, reminiscent of ovarian 
granulosa cell tumors. As expected, the TGFBR1-CAAcre 
females were sterile (Figure 1K). 
Molecular characterization of ovarian tumors
To further define the molecular identity of gonadal 
tumors, we performed immunofluorescence to determine 
tumor cell expression of forkhead box L2 (FOXL2), a 
granulosa cell lineage marker [29], and three additional 
proteins that are abundantly expressed in granulosa cells, 
forkhead box O1 (FOXO1), INHA, and anti-Mullerian 
Figure 2: Molecular characterization of ovarian tumor type in TGFBR1-CAAcre mice. A.-F. Tumors in TGFBR1-CAAcre mice 
express granulosa cell markers. Immunofluorescence of FOXL2 (A and B), FOXO1 (C and D), and INHA (E and F) in the control and 
TGFBR1-CAAcre ovaries. Note the strong localization of all three proteins in the granulosa cells of control (A, C, and E) and tumor tissues 
in the TGFBR1-CAAcre mice (B, D, and F). G. and H. Negative controls using isotype-matched mouse IgG. I.-P. Immunofluorescence of 
KRT8 and KRT17/19 in the control and TGFBR1-CAAcre ovaries. Note that the expression of KRT8 (green; I-L) and KRT17/19 (red; M-P) 
was mainly detected in ovarian surface epithelia of both control and TGFBR1-CAAcre ovaries (yellow arrows), but not in the tumor tissues 
(K, L, O, and P). DAPI was used to counterstain the nucleus. At least 4 control and TGFBR1-CAAcre mice at the age of 2 months were 
analyzed by immunofluorescence and/or immunohistochemistry. Scale bar is representatively shown in (A) and equals 25 µm (I-P) and 50 
µm (A-H).
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hormone (AMH). The expression of FOXL2 (Figure 2A), 
FOXO1 (Figure 2C), INHA (Figure 2E), and AMH (Figure 
S3A-C, G, and H) was confirmed in granulosa cells of 
control ovaries, with representative negative controls 
depicted (Figure 2G and 2H). We found that ovarian 
tumors from TGFBR1-CAAcre mice were immunoreactive 
for FOXL2 (Figure 2B), FOXO1 (Figure 2D), and INHA 
(Figure 2F), supporting the development of granulosa cell 
tumors in these mice. However, expression of AMH was 
low in the tumor tissues (Figure S3D-F and I-K). 
Because granulosa cells may transdifferentiate into 
Sertoli cells in granulosa cell tumors [12], we assessed 
whether there were Sertoli cell-like components in the 
TGFBR1-CAAcre model by immunofluorescence using 
an antibody directed to SRY (sex determining region Y)-
box 9 (SOX9), a Sertoli cell marker (Figure S4). While 
SOX9 was detected in some theca cells of control mice 
(Figure S4A -C) [30], aberrant SOX9 staining was found 
in TGFBR1-CAAcre ovaries (Figure S4D-I). Expression of 
SOX9 in Sertoli cells was included as a positive control 
(Figure S4J and K). 
Since Amhr2-Cre is also expressed in the ovarian 
surface epithelium [31], immunofluorescence was 
performed using antibodies against epithelial cell markers, 
cytokeratin 8 (KRT8) and 17/19 (KRT17/19), to exclude 
the epithelial cell identity of the neoplasms. As expected, 
Figure 3: Histological, immunohistochemical, and hormonal analyses of ovarian tumors in TGFBR1-CAAcre mice at 
late developmental stages. A.-F. H&E staining of control and TGFBR1-CAAcre ovaries demonstrates the arrangement of follicular (C 
and D; 7 month) and trabecular or cord-like (E and F; 6 month) patterns in tumors. Note the hemorrhage in the tumors versus controls 
(A and B; 7 month). n = 3 per group. G.-N. Immunohistochemical staining of FOXL2 and KRT8 in the control and TGFBR1-CAAcre 
ovaries. Panels (H, L, J, and N) represent higher power images for panels (G, K, I, and M), respectively. Note the staining of FOXL2 
in ovarian tumor tissues (K and L) and the expression of KRT8 in discrete cells (M and N) within TGFBR1-CAAcre ovaries. O. Double 
immunofluorescence of KRT8 and INHA. Ovarian samples from control (n = 3) and TGFBR1-CAAcre mice (n = 3) at the age of 6-7 months 
were analyzed by immunofluorescence and/or immunohistochemistry. Scale bar is representatively depicted in (A) and equals 10 µm (H, J, 
L, and N), 15 µm (D and F), 30 µm (B and O) and 300 µm (A, C, E, G, I, K, and M). P.-S. Hormone levels of E2, inhibin B, inhibin A, and 
FSH in the serum of control and TGFBR1-CAAcre mice at the age of 5-7 months. Data are mean ± s.e.m. n = 7-8. *P < 0.05 and **P < 0.01. 
Oncotarget40909www.impactjournals.com/oncotarget
KRT8 and KRT17/19 were localized to ovarian surface 
epithelia of control and TGFBR1-CAAcre mice, with low 
to undetectable expression in the tumor tissues at the age 
of 2 months (Figure 2I-2P). Expression of KRT8 has been 
shown to be increased in mouse granulosa cell tumors 
[12]. We therefore further examined KRT8 expression 
during late stages of tumor development in our model. 
In contrast to the highly organized follicle structures in 
control mice (Figure 3A and 3B), TGFBR1-CAAcre ovaries 
showed pathological changes such as the arrangement of 
follicular (Figure 3C and 3D) and/or trabecular (Figure 
3E and 3F) patterns, the presence of hemorrhage (Figure 
3C-3F), and multifocal necrosis within the center of some 
lobules (Figure S5A and B). The tumors were positive 
for FOXL2 (Figure 3K and 3L), which was expressed in 
control granulosa cells (Figure 3G and 3H). KRT8 was 
predominantly expressed in ovarian surface epithelia of 
controls (Figure 3I and 3J). However, a focal distribution 
of KRT8 in TGFBR1-CAAcre ovaries was evident (Figure 
3M and 3N). Double immunofluorescence revealed low 
Figure 4: Constitutive activation of TGFBR1 in mouse granulosa cells using Cyp19-Cre promotes gonadal tumor 
formation. A. Representative macroscopic images of ovarian tumors in TGFBR1CA Lox/+; Cyp19-Cre mice. Macroscopic tumors were 
observed in TGFBR1CA Lox/+; Cyp19-Cre mice (n = 22) examined at the age of 2-6 months. B.-G. H&E staining of ovaries from control (B 
and E; n = 4) and TGFBR1-CACcre mice (C, D, F, and G; n = 3) at the age of 2 months. Panels (E, F, and G) represent higher power images 
for panels (B, C, and D), respectively. (C) and (D) represent the two ovaries from a TGFBR1CA Lox/+; Cyp19-Cre mouse. Note the formation 
of multiple hemorrhagic ovarian cysts in one ovary (C and F) and hemorrhagic tumor foci in the other (D and G). H. The effect of PMSG 
treatment on ovarian mRNA expression of Fshr and Lhcgr. VEHL, vehicle control. Data are mean ± s.e.m. n = 5. ***P<0.001; two-way 
ANOVA. I.-T. Immunostaining of Ki67, FOXL2, and INHA in control (I-N) and TGFBR1CA Lox/+; Cyp19-Cre ovaries (O-T) of 2-month-
old mice. n = 3. U.-Z. Immunostaining of Ki67, INHA, and KRT8 in TGFBR1CA Lox/+; Cyp19-Cre ovaries during late tumor development. 
Panels (L-N), (R-T), and (X-Z) represent higher power images for panels (I-K), (O-Q), and (U-W), respectively. Images are representative 
of immunohistochemistry analyses performed using 4-6 month old control (n = 3) and TGFBR1CA Lox/+; Cyp19-Cre mice (n = 6). Scale bar is 
representatively depicted in (B) and equals 10 µm (L-N, R-T, and X-Z), 60 µm (E-G), 150 µm (I-K and O-Q), and 300 µm (B-D and U-W). 
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expression or absence of INHA in KRT8-positive cells 
within tumor lobules (Figure 3O), suggesting distinct 
identity of KRT-positive cells. 
Hormone profile of mice harboring a 
constitutively active TGFBR1 in the ovary
Clinically, granulosa cell tumors often secrete 
excessive inhibin and estrogen [32, 33]. Serum inhibin 
is a reliable marker for granulosa cell tumors [34]. To 
determine the relevance of TGFBR1-CAAcre mice as a 
potential model for granulosa cell tumors, we measured 
serum estradiol (E2), inhibin B, inhibin A, and follicle-
stimulating hormone (FSH) levels in control and 
TGFBR1-CAAcre mice. The results showed that serum 
levels of E2, inhibin B, and inhibin A were highly 
elevated in TGFBR1-CAAcre mice versus controls (Figure 
3P-3R). Consistent with the high levels of inhibin, serum 
FSH levels were below detection limit in TGFBR1 
overactivated mice (Figure 3S). These data demonstrate 
that constitutive activation of TGFBR1 promotes 
the development of granulosa cell neoplasms which 
phenocopy certain molecular and hormonal characteristics 
of human granulosa cell tumors. 
Development of complementary mouse models 
by constitutive activation of TGFBR1 using 
additional ovary-expressed Cre lines
Amhr2-Cre is expressed in both ovarian granulosa 
cells and theca cells [35, 36] (Figure S1D). To substantiate 
our findings and determine whether constitutive 
activation of TGFBR1 in the granulosa cells contributes 
to the ovarian tumor phenotype, we generated two 
complementary mouse models that expressed TGFBR1CA 
under the control of cytochrome P450 family 19-Cre 
(Cyp19-Cre) using Tg(CYP19A1-cre)1Jri mice, restricting 
Cre activity to the granulosa cells of antral follicles 
(Figure S1E), particularly those at late follicular stages 
[37]. Both TGFBR1CA Lox/+; Cyp19-Cre and TGFBR1CA 
Lox/Lox; Cyp19-Cre mice (herein termed TGFBR1-CACcre) 
developed ovarian sex cord-stromal tumors, which 
morphologically phenocopied those in Amhr2-Cre mice 
(Figure 4A and Figure S6A). Histological analysis 
demonstrated the formation of hemorrhagic ovarian 
cysts and tumor foci (Figure 4B-4G and Figure S6K-N). 
Consistent with the late onset of Cyp19-Cre expression 
in the ovary [37], ovarian weight was not significantly 
different between TGFBR1CA Lox/+; Cyp19-Cre and control 
mice at 1 month of age. TGFBR1CA Lox/+; Cyp19-Cre 
ovaries contained morphologically identifiable follicles 
at 3 weeks of age (data not shown), allowing further 
assessment of the effect of gonadotropin hormones on 
the differentiation of granulosa cells. The results showed 
that although pregnant mare serum gonadotropin (PMSG) 
could induce the expression of FSH receptor (Fshr) in 
both control and TGFBR1-CACcre ovaries, the induction of 
luteinizing hormone/choriogonadotropin receptor (Lhcgr) 
was substantially compromised in the TGFBR1-CACcre 
ovaries (Figure 4H). Moreover, tumors from TGFBR1-
CACcre ovaries were highly proliferative (Figure 4O, 4R, 
4U, 4X and Figure S6E, H, G, J, O, and P), expressed 
granulosa cell markers FOXL2 (Figure 4P and 4S) and 
INHA (Figure 4Q, 4T, 4V, and 4Y and Figure S6F, I, G, 
J, Q, and R), and were immunoreactive for KRT8 during 
tumor progression (Figure 4W and 4Z and Figure S6S and 
T). Immunostaining of Ki67, FOXL2, and INHA using 
2-month-old control ovaries are representatively depicted 
(Figure 4I-4N and Figure S6B-D).
Results from the TGFBR1-CACcre mice 
demonstrated that overactivation of TGFBR1 in granulosa 
cells led to ovarian tumor development. Unexpectedly, we 
found that constitutive activation of TGFBR1 using GLI-
Kruppel family member GLI1 (Gli1)-CreERT2 (designated 
as TGFBR1-CAGcre; Figure S7A) caused the development 
of INHA-positive ovarian tumors following tamoxifen 
injection (Figure S7B-H). Although signals of red 
fluorescent protein (RFP; a Gli1-Cre reporter) was mainly 
found in theca layers, Gli1-Cre activity was also observed 
in a subset of granulosa cells within some follicles (Figure 
S7I and J) and signals were detected in granulosa cells and 
tumor tissues using TGFBR1 probe by RNAscope (Figure 
S7K-N) in tamoxifen-treated mice, suggesting potential 
overactivation of TGFBR1 in granulosa cell compartment.
Constitutively active TGFBR1 alters ovarian 
cell proliferation, differentiation, and tumor 
microenvironment
An essential step for a normal cell to transform 
to a cancer cell is to acquire the ability of uncontrolled 
proliferation [38]. The highly proliferative nature and 
mitotic activity of tumor cells in the TGFBR1-CAAcre 
ovaries were revealed by the presence of mitotic figures 
(Figure 1H), positive staining of cell proliferation markers 
Ki67 (Figure 5B) and proliferating cell nuclear antigen 
(PCNA; Figure 5C), and expression of mitotic marker 
phospho-histone H3 (pH3; Figure 5D). In control ovaries, 
Ki67 was strongly localized to proliferating granulosa 
cells (Figure 5A). Notably, theca cells positive for ACTA2 
were highly organized in the control ovary (Figure 5A). 
However, ACTA2-positive cells were disoriented and/or 
enriched in the tumor foci (Figure 5B). 
To determine how constitutive activation of 
TGFBR1 in the ovary tipped the cellular homeostatic 
scale in favor of proliferation, we examined the status of 
activation of AKT pathway, which promotes cell growth 
and survival. Western blot demonstrated increased levels 
of phospho-AKT in the TGFBR1-CAAcre ovaries (Figure 
5E). We also found that transcript levels of Gli1 and Gli2, 
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transcription factors that regulate the expression of target 
genes of hedgehog signaling, were highly elevated in 
TGFBR1 constitutively active ovaries (Figure 5F). Given 
the potential importance of GLI transcription factors in 
cancer development [6, 39], our findings suggest that 
TGFβ signaling may interact with hedgehog pathway to 
drive ovarian tumor formation [40-42]. In addition, the 
expression of mRNA transcripts encoding TGFBR3 (also 
known as betaglycan), a critical regulator of inhibin action 
[43], was reduced in the ovary of TGFBR1-CAAcre mice 
compared with controls (Figure 5F). 
Since coordinated cell proliferation and 
differentiation are critical for developmental events, we 
predicted that granulosa cell differentiation would be 
compromised in TGFBR1-CAAcre mice. To test this, we 
analyzed a number of critical genes involved in granulosa 
cell differentiation and function, including Cyp19a1, 
3-β-hydroxysteroid dehydrogenase (Hsd3b), Fshr, 
Lhcgr, estrogen receptor 1 (Esr1), natriuretic peptide 
type C (Nppc), Wnt4, Bmp2, empty spiracles homeobox 
Figure 5: Constitutively active TGFBR1 alters ovarian cell proliferation, differentiation, and angiogenesis. A.-D. 
Immunofluorescence of cell proliferation markers in 2-month-old control and/or TGFBR1-CAAcre ovaries. ACTA2 (green) was utilized 
to mark the follicle structure. Scale bar is representatively depicted in (A) and equals 50 µm (A-D). E. Increased phospho-AKT levels in 
the ovaries of TGFBR1-CAAcre mice by western blot using ovaries from 2-month-old mice. n = 3. Upper panels are representative western 
images and the lower bar graph is the quantification result. Each lane represents an independent sample. F. Increased Gli1/2 and reduced 
Tgfbr3 mRNA abundance in the ovaries of TGFBR1-CAAcre mice (2 month; n = 3) versus controls (n = 4). Data are mean ± s.e.m. *P < 
0.05 and **P < 0.01. G. Dysregulation of genes associated with granulosa cell differentiation and function in the ovaries of 2-month-old 
TGFBR1-CAAcre mice (n = 3) versus controls (n = 4). Data are mean ± s.e.m. *P < 0.05, **P < 0.01, and ***P < 0.001. H. Western blot analysis 
of HSD3B expression. n = 3. Each lane represents an independent sample. ACTB was used as an internal control. I. and J. Angiogenesis 
in ovarian tumors evidenced by immunohistochemical analysis of CD31 expression. Panels (I) and (J) represent the respective control and 
TGFBR1-CAAcre ovaries of 2-month-old mice. n = 4. Scale bar is representatively depicted in (I) and equals 20 µm (I and J). K. Upregulation 
of genes associated with angiogenesis in 2-month-old TGFBR1-CAAcre mice (n = 3) versus controls (n = 4). Data are mean ± s.e.m. *P < 
0.05, **P < 0.01, and ***P < 0.001. L. Hypothetical model depicting potential TGFβ signaling targets (e.g, AKT, GLI1/2, and TGFBR3) 
during ovarian sex cord-stromal tumor development. TGFβ signaling activity is controlled by negative regulators (e.g., inhibitory SMADs 
and BMP signaling). Loss of repression of TGFβ and/or activin signaling by negative regulators promotes SMAD2/3 activation and alters 
cell proliferation and differentiation and angiogenesis. 
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2 (Emx2), and R-spondin 1 (Rspo1). Our results revealed 
dysregulated expression of these genes in TGFBR1-CAAcre 
ovaries (Figure 5G). Moreover, protein expression of 
HSD3B, an enzyme involved in progesterone biosynthesis, 
was also suppressed in the ovary of TGFBR1-CAAcre mice 
(Figure 5H). These studies collectively suggest altered 
granulosa cell differentiation and function during ovarian 
tumor development. 
Angiogenesis is a hallmark of cancer [38]. 
Consistent with the hemorrhagic tumor phenotype, active 
angiogenesis was found in these tumors, evidenced by 
immunostaining of platelet/endothelial cell adhesion 
molecule 1 (PECAM1)/CD31 (Figure 5I and 5J), an 
endothelial cell marker. Double immunofluorescence 
of CD31 and ACTA2 further revealed blood vessel 
formation within tumor foci (Figure S8). Furthermore, 
constitutive activation of TGFBR1 in the TGFBR1-
CAAcre ovaries caused increased expression of mRNA 
transcripts for Acta2, platelet-derived growth factor 
alpha (Pdgfa), integrin beta 3 (Itgb3), and extracellular 
matrix components including collagen type IV, alpha 1 
and 4 (Col4a1 and Col4a4) and matrix metalloproteinase 
2 (Mmp2) (Figure 5K). Taken together, these data 
demonstrate that constitutively active TGFBR1 promotes 
cell proliferation, inhibits cell differentiation, and alters 
tumor microenvironment by enhancing angiogenesis. 
Based on our finding and existing literature, a hypothetical 
model is proposed to depict TGFβ signaling activation in 
gonadal tumor development (Figure 5L).
DISCUSSION
Although in vitro studies have documented roles 
of TGFβ signaling in multifaceted cellular properties 
including proliferation and differentiation, the in vivo 
function of TGFβ signaling in the ovary is poorly defined. 
This knowledge gap is partially due to technical limitations 
of in vitro analysis, particularly cell-based assays, to fully 
address the function of TGFβ signaling from the tissue 
to the organismic level, where the biological response of 
a cell to a given TGFβ signal is contextually dependent 
and influenced by the availability of compensatory 
mechanisms [44]. 
TGFβ proteins inhibit cell proliferation, particularly 
epithelial cells, during early tumor development, but 
promote advanced tumor progression [45, 46]. However, 
transgenic overexpression of TGFβ1 in the skin appears 
to stimulate the growth of quiescent epidermal cells 
[47]. In addition, haploinsufficiency of Tgfbr1 reduces 
the development of Kirsten rat sarcoma viral oncogene 
homolog (KRAS)-driven pancreatic precancer formation, 
uncovering a potential tumor promoting effect of TGFβ 
signaling [45, 48]. On the other hand, TGFβ stimulates the 
growth of cells of mesenchymal origin [45]. Notably, loss 
of BMP signaling receptors (i.e., BMPR1A/BMPR1B) and 
downstream SMADs (i.e., SMAD1/5/8) leads to gonadal 
tumor development and increased expression of TGFβ 
target genes and/or activation of SMAD2/3 [5, 6]. A recent 
study using Smad1/5/4 triple conditional knockout mice 
provides further circumstantial evidence that SMAD4-
mediated TGFβ/activin signaling might be tumorigenic in 
the ovary [49]. 
Based on the above evidence, we postulated 
that overactivation of TGFβ signaling in the ovary 
would promote tumorigenesis. To test this hypothesis, 
we created a mouse model harboring a constitutively 
active TGFBR1 that was conditionally activated by Cre 
recombinase driven by Amhr2 promoter [5, 6]. The rapid 
and fully penetrant tumor phenotype clearly demonstrated 
an oncogenic effect of TGFβ signaling activation in the 
ovary. To our knowledge, this is the first mouse model for 
ovarian tumor development that is driven by constitutively 
active TGFBR1, without the dependence on additional 
oncogenic events such as KRAS activation [31, 45] or 
Neu overexpression [50]. Besides the ovary, we also 
observed myometrial abnormality in the TGFBR1-CAAcre 
mice (unpublished observation), which is in line with our 
recent report demonstrating that sustained activation of 
TGFBR1 using progesterone receptor Cre alters uterine 
morphology [24]. The expression of Amhr2-Cre in several 
ovarian cell types [31, 35, 36] and its potential leaky 
feature [51] may represent a limitation of this mouse 
model. It is noteworthy that the tumor phenotype was not 
restricted to females, and males with constitutively active 
TGFBR1 (i.e., TGFBR1CA Lox/+; Amhr2-Cre) also developed 
testicular tumors (unpublished data that will be described 
in an independent report). 
Generation of constitutively active TGFBR1 in the 
mouse ovary using Cyp19-Cre reproduced ovarian tumor 
phenotype, which corroborated findings from studies using 
Amhr2-Cre. It is interesting to note the focal expression 
of KRT8 in late-stage ovarian tumors in both TGFBR1-
CACcre and TGFBR1-CAAcre mice. Since Cyp19-Cre is not 
expressed in the ovarian surface epithelium (Figure S1E) 
[31], our data suggest that overactivation of TGFBR1 
in ovarian surface epithelial cells is not required for the 
observed KRT8 expression in tumor tissues. However, the 
possibility of the migration of ovarian surface epithelial 
cells into the tumor tissues cannot be excluded. Of note, 
only a limited number of TGFBR1CA Lox/Lox; Cyp19-Cre 
female mice were obtained during the course of the 
experiment because TGFBR1CA Lox/+; Cyp19-Cre male 
breeders were also prone to testicular tumor formation at 
an early reproductive age (Figure S9), presumably due to 
Cyp19-Cre expression in the testis [52]. 
A somewhat unexpected finding was that activation 
of TGFBR1 using inducible Gli1-Cre caused ovarian 
tumor formation. Although Gli1 is known to be expressed 
in theca cells, there is evidence supporting the expression 
of Gli1 mRNA in mouse granulosa cells [6, 53]. This 
could potentially explain the observation of ovarian 
tumor development resulting from TGFBR1CA activation 
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by Gli1-Cre. It is also possible that the Cre is leaky or 
that sustained activation of TGFBR1 in ovarian theca 
cells may confer a rapid GLI1-induced response in the 
granulosa cells, leading to Cre recombinase expression 
and subsequent activation of TGFBR1CA. The exact 
mechanism awaits further elucidation. Nevertheless, the 
complementary mouse models created by the current 
study, particularly the TGFBR1-CACcre models, are 
valuable in future studies to define genes/pathways that 
are related to granulosa cell specific activation of TGFBR1 
during ovarian tumor initiation and progression. 
Our further effort toward understanding how 
constitutively active TGFBR1 in the ovary led to 
tumorigenesis generated the following insights. First, 
it has been shown that TGFβ signaling regulates 
phosphatidylinositol 3-kinase (PI3K)-AKT [54, 55], 
whose activation is widely implicated in cancer cell 
growth and survival [56] and associated with human 
cancer development [57]. TGFBR1 activation increases 
mammary epithelial cell survival and facilitates oncogene-
induced malignant transformation via PI3K-AKT pathway 
[50]. Thus, it is conceivable that activation of AKT, 
as a direct or indirect consequence of TGFβ signaling 
activation, accelerates tumor progression in the TGFBR1-
CAAcre mice. Second, ovarian tumors in TGFBR1-CAAcre 
mice had higher levels of Gli1 and Gli2 mRNAs. The 
expression of Gli genes that encode transcription factor 
effectors of sonic hedgehog signaling is also upregulated 
in the granulosa cell tumors of Bmpr1a/Bmpr1b 
conditional knockout mice [6]. Based on the interplay 
between Hedgehog and TGFβ signaling during ovarian 
carcinogenesis [6, 39], the involvement of TGFBR1-
GLI1/2 signaling axis in granulosa cell tumor development 
seems plausible. Third, we found that Tgfbr3 mRNA 
abundance was reduced in ovarian tissues with sustained 
activation of TGFBR1. TGFBR3 is a determinant of 
the inhibin action/potency [43] and inhibits the survival 
of human granulosa tumor cells [58]. Hence, reduced 
expression of TGFBR3 may facilitate the pathogenesis 
of ovarian tumors via attenuating inhibin function and 
potentiating activin signaling [59, 60].
Emerging evidence indicates that TGFβ signaling 
is activated in human granulosa cell tumors [12, 49, 61]. 
Of note, a recent study has shown that ~97% of adult 
granulosa cell tumors carry a FOXL2 somatic missense 
mutation [62], highlighting a breakthrough in the field of 
granulosa cell tumor research. The fact that target genes of 
mutant FOXL2 in granulosa cells are enriched for TGFβ 
signaling [63] further supports the importance of TGFβ 
signaling in the pathogenesis of human granulosa cell 
tumors. Thus, future studies are needed to test the effect 
of TGFBR1 modulators on the cellular properties and the 
development of human granulosa cell tumors, as may 
yield novel insights into the treatment of these tumors. 
An interesting question raised by this study is 
why gonads are prone to oncogenesis upon constitutive 
activation of TGFBR1. Cancer stem cells (CSCs), a 
potential source of cancer cells within a neoplasm, 
are capable of self-renewal. TGFβ signaling has been 
shown to promote the expression of CD133, a cancer 
stem cell marker, in hepatic epithelial cells, leading to 
tumor formation in the xenograft [64]. It is tempting to 
speculate that constitutively active TGFBR1 promotes 
the acquisition of the stemness of ovarian somatic cells 
to facilitate tumorigenesis. However, little is known 
about CSCs in ovarian sex cord-stromal tumors. It is also 
plausible, as described above, that sustained activation 
of TGFBR1 may alter inhibin/activin signaling activity, 
leading to gonadal tumorigenesis [4, 59, 60]. Further 
studies are needed to address these possibilities.
In summary, we provide genetic evidence for the 
oncogenic effect of TGFβ signaling activation in gonadal 
tumor development. In-depth analysis is expected to 
shed new light on the etiology of ovarian granulosa cell 
tumors. These new mouse models are potentially valuable 
for preclinical testing of targeted therapies to treat ovarian 
granulosa cell tumors. 
MATERIALS AND METHODS
Animals
Animal manipulation is in accordance with the 
guidelines of the Institutional Animal Care and Use 
Committee (IACUC) at Texas A&M University. Protocols 
using laboratory mice for this study were approved by the 
IACUC. Mice were maintained on a C57BL/6; 129SvEv 
genetic background and had access to food and water 
ad libitum. The Amhr2-Cre (Amhr2tm3(cre)Bhr) mice were 
generated as described [65] and expression of Amhr2-
Cre in ovarian somatic cells has been documented [5, 31, 
36]. Cyp19-Cre [Tg(CYP19A1-cre)1Jri] is expressed in 
granulosa cells [66, 67]. Protocols using Gli1-CreERT2 mice 
were performed under the UK Home Office guidelines. 
The Gli1-CreERT2 mice [68] and mice harboring a Cre-
inducible LacZ allele, Gt(ROSA)26Sortm1Sor/J [27], were 
obtained from The Jackson Laboratory. The mice were 
on 129S6/SvEvTac background and crossed to C57BL/6J 
mice for at least four generations according to the supplier. 
Mice containing a latent constitutively active TGFBR1 
were created as described [22]. 
Mouse breeding, genotyping, fertility test, and 
treatment
To conditionally activate TGFBR1 in the ovary, 
mice containing TGFBR1CA were crossed with Amhr2-
Cre or Cyp19-Cre mice. The resultant mice were termed 
TGFBR1-CAAcre and TGFBR1-CACcre, respectively. 
Genotyping and/or DNA recombination analysis of 
Oncotarget40914www.impactjournals.com/oncotarget
TGFBR1CA [22, 23], Amhr2-Cre [69], and Cyp19-Cre [67] 
were conducted using PCR. The age of mice was reported 
as a rounded value when it is not an integer for week/
month. For the fertility test, TGFBR1-CAAcre females 
and controls were caged with proven fertile males at the 
age of 6-8 weeks for a period of 3 months. To determine 
ovarian response to gonadotropin, TGFBR1-CACcre and 
control mice were treated with PMSG (5U) or VEHL 
intraperitoneally (i.p.). Ovarian samples were collected 
for RNA isolation 48 h post PMSG treatment. To activate 
TGFBR1CA in the Gli1-positive cell population, TGFBR1CA 
mice were crossed with mice expressing an inducible Cre 
under the control of Gli1 promoter [68]. Mice harboring 
both Gli1-Cre and TGFBR1CA were designated as 
TGFBR1-CAGcre. To induce Cre expression, 6-8 week-
old TGFBR1-CAGcre mice were injected (i.p.) daily for 
4 days, with 3 mg tamoxifen (Sigma) on day 1, and 2 
mg on days 2, 3, and 4. Mice were sampled 4 days after 
induction for in situ TGFBR1 mRNA expression analysis 
(RNAscope) or when clinical signs of tumors developed. 
RFP expression  experiment was performed 7 days after 
mice carrying both Gli1-CreERT2 and Lox-Stop-Lox (LSL)-
RFP reporter were treated with tamoxifen [70]. 
Histological analysis
Ovarian samples were collected from control and 
experimental mice and processed for histological analysis. 
A standard protocol was used for hematoxylin and eosin 
(H&E) staining. Microscopic images were captured using 
DP25 (Olympus) digital camera interfaced with cellSens 
Imaging Software. 
Immunofluorescence microscopy and 
immunohistochemistry
Immunofluorescence and immunohistochemistry 
were performed using serial paraffin sections (5 μm) [18], 
with primary antibodies listed in Table S1. Secondary 
antibodies for immunofluorescence were conjugated with 
Alexa Fluor 488 or 594. The sections were mounted using 
ProLong Gold Slowfade media containing 4’,6-diamidino-
2-phenylindole (DAPI; Invitrogen). Images were 
captured using IX73 microscope (Olympus) interfaced 
with an XM10 CCD camera and cellSens Software. 
Immunohistochemistry was performed using avidin-biotin 
complex (ABC) method as described [18]. Signals were 
developed using VECTOR NovaRED. Negative controls 
where primary antibodies were replaced by isotype-
matched IgGs from the same species were included. 
RNAscope
Chromogenic RNAscope (Advanced Cell 
Diagnostics, Hayward, CA) was performed on formalin-
fixed paraffin-embedded sections using TGFBR1 probe 
(Hs-TGFBR1, Cat no. 431041) accordingly to the 
manufacturer instructions. 
Western blot
Protein samples were prepared and quantified 
as described [19]. Approximately 30 µg of proteins 
were resolved on 12% Mini-PROTEAN TGX Precast 
Gels (Bio-Rad) and then transferred to polyvinylidene 
difluoride (PVDF) membranes (Bio-Rad). The membranes 
were incubated with primary antibodies (Table S1) at 4 
°C overnight, followed by incubation with horseradish 
peroxidase (HRP)-conjugated donkey anti-rabbit antibody 
or anti-goat antibody (1:20,000 in 5% milk; Jackson 
ImmunoResearch) at room temperature for 1 h. Immobilon 
Western Chemiluminescent HRP Substrate (Millipore) 
was used to develop the signals. Blots were scanned 
using a Kodak Image Station 4000 mm PRO. Beta actin 
(ACTB) was included as an internal control to normalize 
potential variations among protein samples. Quantification 
of western blot was performed using ImageJ (NIH, 1.47v). 
Hormone analyses
Serum E2, inhibin B and A, and FSH levels were 
measured using the Ligand Assay and Analysis Core at 
the Center for Research in Reproduction, University 
of Virginia. Assay details can be found at https://med.
virginia.edu/research-in-reproduction/laboratory-facilities/
assay-methods/.
X-gal staining
Ovarian samples from mice harboring 
Gt(ROSA)26Sortm1Sor/J; Amhr2-Cre or 
Gt(ROSA)26Sortm1Sor/J; Cyp19-Cre were fixed in 2% 
paraformaldehyde and 0.2% glutaraldehyde (pH 7.4) for 
15 min at 4°C. The samples were washed and then stained 
using 1 mg/ml X-gal solution containing 5 mM potassium 
ferricyanide and 5 mM potassium ferrocyanide. After 
staining, the ovaries were processed for post-fixation, 
paraffin embedding, sectioning, and counter staining using 
fast red [18]. 
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RNA isolation, conventional PCR, and real-time 
PCR
Total RNA from mouse ovaries was isolated 
using RNeasy Mini Kit (Qiagen). Reverse transcription 
of complementary DNA (cDNA) was then conducted 
as described [18]. For conventional PCR, TGFBR1CA 
was amplified from ovarian cDNA using oligo primers 
(Forward: 5’- TTGTGAACAGAAGTTAAGGC-3’; 
Reverse: 5’- AGCATAATCAGGAACATCAT-3’) [22]. 
PCR products were separated using 1% agarose gel 
containing ethidium bromide. Real-time RT-PCR (qPCR) 
was performed on a CFX Connect Real-time PCR 
Detection System (Bio-Rad) using iTaq Universal SYBR 
Green Supermix (Bio-Rad), cDNA, and gene specific 
primers (Table S2) in a total volume of 10 μl. The PCR 
conditions were described elsewhere [69]. Amplification 
of ribosomal protein L19 (Rpl19) was included as an 
internal control, and calculation of relative levels of gene 
expression was based on DDCT method [71]. 
Statistical analyses
All statistical analyses were performed using 
IBM Statistical Package for the Social Sciences (SPSS; 
Version 23) except the survival rate analysis by Mantel-
Cox test using GraphPad Prism 6 software. Two sample 
independent t-test (unpaired) was performed to determine 
difference between two means. The homogeneity of 
variance was assessed using Levene’s test. Two-way 
analysis of variance (ANOVA) was applied to determine 
the effect of gonadotropin on granulosa cell differentiation. 
Data are presented as mean ± standard error of the mean 
(s.e.m) unless otherwise specified. Statistical significance 
was defined at P < 0.05. Results are marked as *P < 0.05, 
**P < 0.01, and ***P < 0.001.
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